Funding
← Back to your selection

SR One

Activity from announced rounds

Activity in this selectionChina · Oct 25, 2026 · Jan 1, 2026
Rounds participated in
1
Confirmed lead rounds
0
All roles disclosed
New companies
1
First participation on record · 0 follow-on
Funding in participating rounds
—
0 disclosed · full round size, not this investor’s share

By stage

Series C+1

By primary sector

Biotech1

By country

China1

Rounds

1 in this selection
Corxel Pharmaceuticals

Corxel Pharmaceuticals develops clinical-stage medicines for cardiometabolic diseases, including obesity, diabetes, stroke and hypertension.

≤$287MSeries D1
Participant